Piccadily Agro Industries Reports Q2 FY2025-26 Earnings Growth of 15%

Piccadily Agro Industries Limited has reported a **15% growth** in earnings for the second quarter of fiscal year 2025-26, which ended on September 30, 2025. This growth reflects the company's ongoing

7 November 2025
5 min read

Piccadily Agro Industries Limited has reported a 15% growth in earnings for the second quarter of fiscal year 2025-26, which ended on September 30, 2025. This growth reflects the company's ongoing success in its distillery business, particularly within the Indian Made Foreign Liquor (IMFL) segment. The firm has seen sustained demand for its products both domestically and internationally, supported by the commissioning of its expansion project in Indri aimed at increasing malt and ethanol capacity. The company’s management emphasized that they are well-positioned to meet rising consumer demands due to their ongoing procurement of barrels.

The company’s performance in the first half of FY2025-26 (April 1 to September 30, 2025) continues to be bolstered by strategic expansions, particularly in Chhattisgarh, where operations are progressing as planned. Piccadily Agro is also exploring new avenues for growth in its sugar business, along with potential organic and inorganic opportunities in the alcoholic beverage sector, including ready-to-drink (RTD) products. As part of its strategic initiatives, the company is also pursuing excise approval to utilize full capacity at its Indri facility, which is crucial for sustaining production levels to meet increasing demand.

Overall, Piccadily Agro Industries is positioned for continued growth in the competitive beverage market, with its recent earnings report reflecting a robust operational strategy and a commitment to innovation. The management underscored the importance of adapting to evolving consumer preferences and maintaining a focus on excellence and leadership in the industry. As the company navigates potential uncertainties in the market, its dedication to expanding product lines and enhancing production capabilities remains paramount.